Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Serono/Dr. Reddy's Biosimilars Deal Includes Co-Commercialization In U.S.

This article was originally published in The Pink Sheet Daily

Executive Summary

In most of the world, Germany's Merck Serono will have exclusive rights and India’s Dr. Reddy's will receive royalties on the oncology biosimilars which will be developed as part of the collaboration; but in the U.S. and select emerging markets, the Indian company retains co-commercialization rights.

You may also be interested in...



Merck KGaA Draws A Line Under “Old” R&D, Now Seeks More Deals

Germany’s Merck KGaA has streamlined its R&D pipeline, concentrating on immuno-oncology, early-stage compounds and collaborative efforts with partners, and discontinuing expensive late-stage products that were going nowhere.

Deals Of The Week: Pfizer Goes For An IPO

Pfizer’s strategy is to monetize part of its animal health division while continuing new CEO Ian Read’s increased focus on biopharmaceuticals.

Post Biocon, Pfizer Pushes Forward On Biosimilar MABs

Biosimilars pioneers face a steep learning curve and multiple surprises, as shown by Pfizer’s recent and expensive backtrack on its deal with India’s Biocon. But Pfizer says the setback has reaffirmed its strategy as it pushes ahead on its own with a monoclonal antibody program, led by a biosimilar rituximab.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074246

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel